NeuroOne Releases Evo sEEG Electrodes in the U.S.

NeuroOne has commercially launched its Evo sEEG electrode product line in the U.S.
 
Zimmer Biomet has exclusive distribution rights to the Evo Cortical and sEEG product lines, and the Evo line is expected to utilize Zimmer Biomet’s ROSA One Brain, a robotic platform that helps to plan and perform complex, minimally invasive neurosurgical procedures.
 
Dave Rosa, CEO of NeuroOne, told the press, “The commercial launch of the Evo sEEG platform represents one of the most impactful milestones in our company’s history. Paired with Zimmer Biomet’s ROSA One Brain robotic platform and broad distribution network, we believe the Company is well positioned in the market given the synergies that exist between our novel thin film electrode platform and Zimmer Biomet’s robotic platform. Importantly, this new technology potentially provides NeuroOne with a steady and predictable new revenue stream. We expect to complete our initial case within the next 30 days.”
 
NeuroOne offers its full line of electrode tech to an approximate U.S. market of $100 million for patients needing diagnostic brain mapping procedures. Epilepsy mapping procedures mainly use sEEG electrodes because of their less invasive insertion procedure, yet under 5% of those with drug-resistant epilepsy who are surgical candidates undergo diagnostic procedures using sEEGs.
 
NeuroOne’s sEEG electrode technology offers stereoelectroencephalography recording, brain stimulation, and future capabilities for spinal cord stimulation, and ablation solutions targeted for patients suffering from epilepsy, chronic back pain, and Parkinson’s disease.
 
In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.